Prediction of early non response to anti-TNF and methotrexate combination therapy in rheumatoid arthritis patients eligible to first line anti-TNF treatment based on gene expression analysis of whole blood

Trial Profile

Prediction of early non response to anti-TNF and methotrexate combination therapy in rheumatoid arthritis patients eligible to first line anti-TNF treatment based on gene expression analysis of whole blood

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 30 Oct 2012 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
    • 17 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top